

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:	
<input type="checkbox"/>	Preliminary Proxy Statement
<input type="checkbox"/>	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
<input type="checkbox"/>	Definitive Proxy Statement
<input checked="" type="checkbox"/>	Definitive Additional Materials
<input type="checkbox"/>	Soliciting Material under §240.14a-12

HAEMONETICS®

HAEMONETICS CORPORATION

(Name of Registrant as Specified in Its Charter)

Payment of Filing Fee (Check the appropriate box):	
<input checked="" type="checkbox"/>	No fee required.
<input type="checkbox"/>	Fee paid previously with preliminary materials.
<input type="checkbox"/>	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



C 1234567890



ENDORSEMENT_LINE _____ SACKPACK _____
|||

1000000
MR A SAMPLE
DESIGNATION (IF ANY)
ADD 1
ADD 2
ADD 3
ADD 4
ADD 5
ADD 6



Online
Go to www.envisionreports.com/HAE or scan the QR code – login details are located in the shaded bar below.



Votes submitted electronically must be received by 11:59 p.m., Eastern Time, on Thursday, August 3, 2023.

Shareholder Meeting Notice

1234 5678 9012 345

Important Notice Regarding the Availability of Proxy Materials for the Haemonetics Corporation Annual Meeting of Shareholders to be Held on Friday, August 4, 2023

Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the 2023 Annual Meeting of Shareholders of Haemonetics Corporation are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the meeting are on the reverse side. Your vote is important!

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement and the Company's Annual Report to Shareholders for the fiscal year ended April 1, 2023 are available at:

www.envisionreports.com/HAE



Easy Online Access – View your proxy materials and vote.

- Step 1:** Go to www.envisionreports.com/HAE.
- Step 2:** Click on **Cast Your Vote** or **Request Materials**.
- Step 3:** Follow the instructions on the screen to log in.
- Step 4:** Make your selections as instructed on each screen for your delivery preferences.
- Step 5:** Vote your shares.

When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.



Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the Company's proxy materials, you must request it. Paper copies of the proxy materials will include the form of proxy card. There is no charge to you for requesting a copy. Please make your request for a copy as instructed on the reverse side on or before July 21, 2023 to facilitate timely delivery.



2 N O T

C O Y



Shareholder Meeting Notice

The 2023 Annual Meeting of Shareholders of Haemonetics Corporation (the “Company”) will be held on Friday, August 4, 2023 at 125 Summer Street, Boston MA 02110, at 8:00 A.M. Eastern Time.

Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations.

The Board of Directors recommends a vote **FOR** the election of each director nominee, **FOR** Proposals 2, 4 and 5 and for **1 YEAR** on Proposal 3.

Proposals to be considered at the meeting:

1. To elect the eight director nominees named in the proxy statement to one-year terms expiring in 2024;
2. To approve, on an advisory basis, the compensation of our named executive officers;
3. To approve, on an advisory basis, the frequency of future advisory votes on the compensation of our named executive officers;
4. To approve an amendment and restatement of the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan;
5. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 30, 2024; and
6. To transact such other business as may properly come before the meeting.

PLEASE NOTE – THIS IS NOT A PROXY CARD. YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must vote online or request a paper copy of the proxy materials, which will include a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you.

Shareholders of record as of the record date are invited to attend the 2023 Annual Meeting of Shareholders and vote in person. Instructions on attending, gaining admission and voting at the meeting can be found in the proxy statement.



Here’s how to order a copy of the proxy materials and select delivery preferences:

Current and future delivery requests can be submitted using the options below.

If you request an email copy, you will receive an email with a link to the current meeting materials.

PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

- **Internet** – Go to www.envisionreports.com/HAE. Click Cast Your Vote or Request Materials.
- **Phone** – Call us free of charge at 1-866-641-4276.
- **Email** – Send an email to investorvote@computershare.com with “Proxy Materials Haemonetics Corporation” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by July 21, 2023.